Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

meningitis B

- PMLiVE

FDA accepts review to broaden GSK’s Zejula label

Seeks approval in advanced ‘all-comer’ ovarian cancer population

- PMLiVE

GSK pays $50m upfront to tap Immatics’ cell therapy platform

Deal focuses on T cell receptor therapies

- PMLiVE

GSK considers more divestments to help R&D push

Turns priority to future growth drivers and R&D investment

- PMLiVE

HIV vaccine based on Sanofi/GSK components fails trial

Data suggested vaccine was no more effective than placebo

- PMLiVE

GSK and Gilead join global efforts to tackle novel coronavirus

Confirmed cases rise to over 17,000 in China

- PMLiVE

GSK licenses its tuberculosis vaccine to Gates MRI

Vaccine has demonstrated around 50% efficacy in preventing disease

- PMLiVE

FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

If approved will become first BCMA targeting drug for myeloma

- PMLiVE

GSK divests travel vaccines to Bavarian Nordic as part of strategic refocus

Agreed divestment deal is worth up to €955m

- PMLiVE

GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

Pricing pressures increase amid intense political scrutiny

- PMLiVE

FDA rejects ViiV’s long-acting monthly HIV injection

Blow to company as it hopes to capture market share from Gilead

- PMLiVE

Lynparza cleared for first-line ovarian cancer use in China

Continues to cement lead in PARP inhibitor category

- PMLiVE

Nucala works in rare inflammatory disease, says GSK

Company is planning to file for approval in indication next year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links